Oncotarget

Meta-Analysis:

Statin use and endometrial cancer risk: a meta-analysis

Jing Yang, Qiaoling Zhu, Qiao Liu, Yingxia Wang, Weimin Xie _ and Lili Hu

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2017; 8:62425-62434. https://doi.org/10.18632/oncotarget.18658

Metrics: PDF 534 views  |   HTML 698 views  |   ?  


Abstract

Jing Yang1,2, Qiaoling Zhu2, Qiao Liu2, Yingxia Wang2, Weimin Xie1 and Lili Hu3

1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Hunan Province, Changsha, China

3Department of Obstetrics and Gynecology, Jilin Central Hospital, Jilin, China

Correspondence to:

Weimin Xie, email: xwm315423@163.com

Keywords: statin, endometrial cancer, cancer risk, meta-analysis

Received: March 17, 2017     Accepted: May 04, 2017     Published: June 27, 2017

ABSTRACT

Several studies have evaluated the association between statin use and endometrial cancer risk. We carried out a meta-analysis of randomized controlled trials (RCTs) and non-randomized studies to evaluate the effect of statins on endometrial cancer risk. A comprehensive search of electronic databases, conference abstracts and clinical trial registers was conducted for published and unpublished results. Studies that evaluated exposure to statins and endometrial cancer risk were considered. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using either a fixed-effects or a random-effects model. Two RCTs and eleven non-randomized studies (four cohort and seven case-control studies) involving 9,517 cases of endometrial cancer were included in the analysis. There was no evidence of an association between statin use and endometrial cancer risk either among RCTs (RR, 0.72; 95% CI, 0.19 to 2.67) or among non-randomized studies (RR, 0.94; 95% CI, 0.82 to 1.07). Combined analysis of all included studies also showed that statin use did not significantly affect endometrial cancer risk (RR, 0.94; 95% CI, 0.82 to 1.07). The sensitivity analysis confirmed the stability of our results. Our findings do not support a protective effect of statins against endometrial cancer at the population level.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18658